Published human trials describe what a triple agonist does in a clinical setting. We supply the compound, and the proof of what is in the vial.
Reported at 48 weeks in the 12 mg arm of the published phase 2 trial, against 2.1% on placebo.
GIP, GLP-1 and glucagon receptor activity studied together for additive effects on appetite, insulin signalling and energy expenditure.
The TRIUMPH programme is studying retatrutide in obesity, type 2 diabetes, knee osteoarthritis and obstructive sleep apnoea.
Figures describe published human clinical research on the compound. Apex Biohacks supplies {{ productName }} for in-vitro laboratory research only and makes no claims about its use.
Semaglutide works on one. Tirzepatide on two. Retatrutide is the first to be studied across all three incretin-axis receptors at once.
The pathway semaglutide acts on. Studied for satiety signalling and slower gastric transit.
The second receptor behind tirzepatide. Studied for glucose-dependent insulin release and fat-tissue metabolism.
The glucagon receptor is what sets retatrutide apart. Studied for lipid oxidation and raised energy expenditure.
{{ orderSub }}
+
Every lot goes to Brown Biology Lab, an ISO-17025-accredited, A2LA-certified independent facility, before it leaves our floor. The CoA in your box is the one anyone can pull from the public library.
Procurement-specific question? Email research@apexbiohacks.com — we typically reply the same business day.
All our products are for in-vitro research use only by qualified professionals. Not for human or animal use.
By entering, you confirm that you are a qualified researcher and accept our Terms, Privacy Policy, and Research Use Only Disclaimer.
We use essential cookies to run the site and, with your consent, analytics and marketing cookies to improve your experience. You can change your choice anytime. See our Privacy Policy.